Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression

Abstract Background Glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains uniformly fatal due to the lack of effective targeted therapies. The epidermal growth factor receptor (EGFR) is the most frequently altered receptor tyrosine kinase oncogene in GBM with most alte...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mylan R. Blomquist, Teresa M. R. Noviello, Christopher Sereduk, Dustin Grief, Francesca P. Caruso, Ritin Sharma, Krystine Garcia-Mansfield, Patrick Pirrotte, Jean Kloss, Fulvio D’Angelo, Bianca M. Marin, Kendra Porath, Sonia Jain, Benjamin Rabichow, Shannon P. Fortin Ensign, Antonio Iavarone, Antonella Paladino, Jann N. Sarkaria, Joseph C. Loftus, Michele Ceccarelli, Nhan L. Tran
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-10-01
coleção:	Journal of Translational Medicine
Assuntos:	Glioblastoma EGFR Resistance Antibody drug conjugate
Acesso em linha:	https://doi.org/10.1186/s12967-025-07216-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!